Martin Marietta Materials, Inc. (MLM) is scheduled to report first-quarter 2025 results on April 30, before market open.In the last reported quarter, the company reported mixed results, with earnings beating the Zacks Consensus Estimate by 4.1% but revenues missing the same by 1.3%. Both the top and bottom lines increased 1% and 3% on a year-over-year basis, respectively.Martin Marietta’s earnings topped the consensus mark in two of the last four quarters and missed on two occasions, with an average negativ ...

Core Viewpoint - Forum Energy Technologies (FET) is expected to report first-quarter earnings on May 2, 2025, with earnings estimated at 43 cents per share and revenues at $196.3 million, reflecting a significant year-over-year earnings increase but a slight revenue decline [1][2]. Group 1: Earnings Expectations - The Zacks Consensus Estimate for FET's earnings indicates a 458.3% year-over-year increase [2] - Revenue estimates suggest a 3% decline compared to the previous year's actual figures [2]. Group 2: Business Operations - FET generates income primarily through manufacturing and selling consumable and capital equipment products, with additional revenue from rental services and aftermarket technical services [3]. - The company has seen a 15% year-over-year increase in market share in 2024, attributed to its focus on niche markets and differentiated technologies [4]. Group 3: Cost and Market Challenges - Rising costs, particularly in the fourth quarter, were driven by higher cost of sales and increased operating expenses, contributing to a net loss of $103.5 million [5]. - Management noted inflationary pressures and commodity price volatility, with expectations of a 2-5% decline in global drilling and completion activity in 2025, which may continue to impact margins [6]. Group 4: Earnings Prediction Model - The current model does not predict an earnings beat for FET, as the Earnings ESP is 0.00% and the Zacks Rank is 3 (Hold) [7][8].

Brookfield Renewable Partners (BEP) is scheduled to release first-quarter 2025 results on May 2, before market open. The company delivered an earnings surprise of 50% in the last reported quarter. (See the Zacks Earnings Calendar to stay ahead of market-making news.)Let’s discuss the factors that are likely to be reflected in the upcoming quarterly results.Key Factors That Might Have Impacted BEP's Q1 PerformanceBrookfield Renewable Partners’ first-quarter earnings are expected to have continued to benefit ...

Core Viewpoint - Amgen is set to report its first-quarter 2025 results on May 1, with expectations of strong sales driven by volume growth in key products, although pricing pressures may impact overall revenue [1][4]. Sales Estimates - The Zacks Consensus Estimate for first-quarter sales is $7.96 billion, with earnings expected at $4.16 per share [1]. - Specific sales estimates for key products include Evenity at $406 million, Repatha at $616 million, Kyprolis at $381 million, and Blincyto at $333 million [2]. Patent Expiration Impact - Patents for Prolia and Xgeva expired in February 2025 in the U.S., leading to anticipated significant sales erosion due to biosimilar competition, with estimates of $990 million for Prolia and $542 million for Xgeva [3]. New Product Contributions - Newer drugs like Tezspire and Tavneos are expected to contribute positively to top-line growth, alongside the successful launch of Imdelltra for advanced small cell lung cancer [4]. Declining Sales of Established Products - Sales of Enbrel and Otezla are projected to decline due to price reductions and historical trends related to benefit plan changes and increased co-pay expenses [5][6]. Biosimilars Performance - Increased competition is expected to negatively impact revenues from oncology biosimilars, while sales of Amjevita/Amgevita are likely to have increased [7]. - Amgen launched biosimilars Wezlana and Pavblu, with investors keenly observing their sales performance [8]. Operating Margin Expectations - Amgen anticipates the lowest operating margin of the year at around 42% for the first quarter, with R&D costs expected to rise while SG&A costs as a percentage of sales are projected to decline [9]. Earnings Surprise History - Amgen has a strong earnings surprise history, beating estimates in the last four quarters with an average surprise of 5.23% [10]. Earnings Prediction Model - The current model does not predict a definitive earnings beat for Amgen, with an Earnings ESP of -0.05% and a Zacks Rank of 3 [12].

Core Viewpoint - Vulcan Materials Company (VMC) is set to release its first-quarter 2025 results on April 30, with expectations of revenue growth driven by strong pricing and stable demand despite challenges in certain segments [1][3]. Financial Performance - In the last reported quarter, Vulcan's adjusted earnings and revenues exceeded the Zacks Consensus Estimate by 23.3% and 1.4%, respectively, with year-over-year increases of 48.6% and 1.1% [1]. - The Zacks Consensus Estimate for VMC's first-quarter earnings per share is 80 cents, unchanged over the past 30 days, indicating no year-over-year change. Revenue is estimated at $1.68 billion, reflecting an 8.7% year-over-year increase [2]. Revenue Drivers - Anticipated revenue growth in the first quarter is attributed to strong pricing gains across product lines, recent acquisitions, and stable demand in the legacy business. Public construction activity is expected to offset a decline in private construction [3]. - The Aggregates business, which includes crushed stone, sand, and gravel, is projected to contribute significantly to revenue, with net sales expected to grow 10.8% to $1.43 billion. Aggregates volumes and prices are anticipated to increase by 3.9% and 6.8%, respectively [5]. - The Asphalt Mix segment is expected to see net sales of $195.5 million, indicating a 5% growth year-over-year, with volumes and prices projected to grow by 2.2% and 2.8%, respectively [6]. - Conversely, the Concrete segment is expected to decline by 10.9% to $132.1 million, with volumes down 12.2% but prices up by 1.5% [7]. Operational Challenges - Higher cost inflation, skilled labor shortages, and rising wage expenses are anticipated to impact VMC's margins in the first quarter. The company is focused on improving operational efficiencies through its Vulcan Way of Operating [8]. Earnings Prediction - The current model does not predict an earnings beat for Vulcan, with an Earnings ESP of -5.39% and a Zacks Rank of 3 (Hold) [9][10].

Core Viewpoint - Linde plc is expected to report its first-quarter 2025 results on May 1, with positive indicators from previous quarters suggesting a potential earnings beat due to strong performance in the Americas segment and favorable pricing dynamics [1][7]. Group 1: Previous Quarter Performance - In the last reported quarter, Linde's earnings were $3.97 per share, surpassing the Zacks Consensus Estimate of $3.93, driven by higher pricing and increased volumes from the Americas segment [2]. - Linde has consistently beaten the Zacks Consensus Estimate in the last four quarters, with an average surprise of 1.45% [2]. Group 2: Earnings Estimates - The Zacks Consensus Estimate for first-quarter earnings per share is $3.93, reflecting a 4.8% improvement from the prior-year quarter [3]. - The revenue estimate for the first quarter is $8.26 billion, indicating a year-over-year increase of 1.96% [3]. Group 3: Contributing Factors - Linde's position as a global leader in industrial gases, including oxygen, hydrogen, and nitrogen, supports its performance across various end markets such as healthcare and manufacturing [4]. - The Americas segment is expected to contribute significantly to profits, with operating profit estimated at $1.16 billion, up from $1.12 billion in the first quarter of 2024 [6]. - The Engineering business unit's operating profit is estimated at $96 million, an increase from $93 million a year ago, indicating overall positive demand and pricing dynamics [6]. Group 4: Earnings Prediction - The company's Earnings ESP is +0.30%, suggesting a strong likelihood of an earnings beat, supported by a Zacks Rank of 3 [7].

Core Viewpoint - Baxter International Inc. is expected to report first-quarter 2025 results on May 1, with a consensus estimate for revenues at $2.57 billion, reflecting a 28.4% decline year-over-year, and earnings per share (EPS) estimated at 48 cents, indicating a 26.2% year-over-year decline [1][2]. Revenue Estimates - The consensus estimate for total revenues is $2.57 billion, which represents a significant decline of 28.4% from the prior-year quarter [1]. - The model estimates total revenues from continuing operations to improve by 3.8% at constant currency to $2.58 billion [2]. Growth Factors - Baxter is likely to report moderate growth due to strong momentum in certain product lines, aided by easing macroeconomic pressures, with sales from continuing operations improving by 2% at constant currency in Q4 2024 [3]. - The company anticipates sales growth from continuing operations to be in the range of 3-4% [3]. Margin and Cost Considerations - Margins declined in the last reported quarter primarily due to one-time costs, including goodwill impairment charges and business optimization costs, which are expected to be reduced in the first quarter, potentially boosting the bottom line [4]. - The completion of a transformational plan, including the spin-off of certain business segments, is expected to enhance operational efficiency and improve EPS to a range of 47-50 cents [5]. Impact of Hurricane Helene - Baxter's recovery from Hurricane Helene has ensured minimal disruption in 2025, with all manufacturing lines restored to pre-hurricane levels, securing supply continuity [6]. - The Medical Products & Therapies segment is expected to have recovered from the hurricane's impact, aiding sales during the first quarter [7]. Segment Performance - Strong growth in infusion therapies, particularly the Novum IQ pump platform, is expected to continue, contributing positively to sales [8]. - The growth of parenteral nutrition products and Advanced Surgery products, along with recovery in IV solutions sales, is anticipated to drive segmental sales up by 6.6% at constant currency to $1.28 billion [9]. - The Healthcare Systems & Technologies segment may face challenges due to softness in the U.S. primary care market and delays in international capital spending, but patient support systems are expected to show resilience [10]. - The Pharmaceuticals segment is likely to improve, driven by a rebound in injectable drug sales and strong demand in drug compounding, with estimated sales growth of 14.4% at constant currency to $280.4 million [12][13].

Core Viewpoint - Humana Inc. is expected to report strong first-quarter 2025 results, with earnings projected at $9.98 per share and revenues at $32.22 billion, indicating significant year-over-year growth [1][3]. Financial Performance - The first-quarter earnings estimate reflects a 38% year-over-year increase, while revenues are expected to grow by 9.8% [1]. - For the current year, Humana's revenue consensus estimate stands at $126.55 billion, representing an 8% year-over-year rise, and the EPS consensus is $16.36, indicating a growth of approximately 0.9% [3]. Earnings Expectations - Humana has consistently beaten earnings estimates in the past four quarters, with an average surprise of 15.4% [3]. - The company has a positive Earnings ESP of +0.57% and a Zacks Rank of 3 (Hold), suggesting a likelihood of an earnings beat this quarter [4]. Revenue Drivers - Revenue growth in Q1 is anticipated to be driven by higher premiums, with the consensus estimate for premiums at $30.7 billion, reflecting an 8.6% year-over-year increase [5]. - Revenues from Medicare stand-alone PDPs are expected to reach $1.7 billion, indicating a substantial year-over-year increase of 110.8% [5]. Membership Trends - Despite the expected revenue growth, total medical memberships are projected to decline by 3.8% year-over-year, primarily due to decreases in individual Medicare Advantage units and ASO commercial memberships [6]. Operating Expenses - Total operating expenses for the Insurance segment are estimated to grow by 7.6% year-over-year, attributed to higher operating costs [7].

Core Viewpoint - International Paper Company is set to report its first-quarter 2025 results on April 30, following the acquisition of DS Smith, which is expected to significantly enhance its financial performance compared to the previous year [1][2]. Financial Performance Expectations - The Zacks Consensus Estimate for International Paper's first-quarter revenues is $6.61 billion, reflecting a 43.1% increase from the same quarter last year [3]. - Earnings estimates have decreased by 16.7% over the past 60 days to 35 cents per share, indicating a 106% year-over-year increase from 17 cents reported in the previous year [3]. - The company has a history of earnings surprises, beating estimates in three of the last four quarters with an average surprise of 41.5% [5]. Segment Performance Insights - EMEA Packaging volumes are projected to reach 2,452 thousand short tons in Q1 2025, a significant increase from 340 thousand tons in Q1 2024, with revenues expected at $2.44 billion [7]. - North American Packaging Solutions is anticipated to see year-over-year volume increases in various categories, with revenues estimated at $3.79 billion for the quarter [8][9]. - Overall, Industrial Packaging segment volumes are projected at 6,165 thousand short tons, indicating a 54.5% year-over-year rise, with revenues expected to be $6.2 billion, reflecting a 62.9% increase [10]. Operating Profit Projections - The Industrial Packaging segment's operating profit is expected to surge by 73% to $373 million, with North American Packaging Solutions projected at $285 million and EMEA Packaging at $87.7 million [11]. Global Cellulose Fibers Segment - The Global Cellulose Fibers segment is expected to report volumes of 622 thousand metric tons, a 14.7% year-over-year decline, with revenues estimated at $608 million, down 13.6% from the previous year [12]. Stock Performance - International Paper's stock has increased by 39.1% over the past year, outperforming the industry average growth of 23.6% [14].

Dominion Energy Inc. (D) is expected to report an improvement in the bottom line when it reports first-quarter 2025 results on May 1, before market open. (See the Zacks Earnings Calendar to stay ahead of market-making news.)The Zacks Consensus Estimate for D’s first-quarter revenues is pegged at $3.85 billion, indicating a 6.02% increase from the year-ago reported figure.The consensus estimate for earnings is pegged at 77 cents per share. The Zacks Consensus Estimate for D’s first-quarter earnings indicates ...